2010年12月1日
In a recent Investor’s Business Daily article, CSOFT’s Matt Arney was quoted as saying, “The next real challenge for Chinese companies (is) going global — some will make it, some will not. A good litmus test for telling how well a Chinese company will deal with cultural differences is to look at its executive team. Hopefully, there will be some diversity in the management structure: Chinese educated overseas, or Americans or Europeans on their management team”.
About Investor’s Business Daily:
“Investor’s Business Daily provides exclusive stock lists, stock market research, education, and the latest financial and business news to help investors make more money in the stock market. All of IBD’s products and features are based on the CAN SLIM® Investing System developed by IBD’s Founder William J. O’Neil, who identified the seven common characteristics that winning stocks display before making huge price gains.”
Click here for the whole article.
About CSOFT Health Sciences
CSOFT Health Sciences, leaders in clinical trial localization, provides AI/ML-enabled medical translation services for all phases of the drug and medical device product lifecycle, from development to post-launch. We also specialize in DCT solutions, linguistic validation, and CTD/eCTD submissions with the FDA, EMA, and NMPA. Our operations are certified in ISO 17100:2015, ISO 9001:2015, and ISO 13485:2016, ensuring our customized solutions meet the rigorous regulatory requirements of MMA, NDA, CTA, and Medical Device Application submissions. www.csoftintl.com
